Dexcel Pharma Technologies Ltd. 13D and 13G filings for Roivant Sciences Ltd.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 06:51 am Unchanged | 2023-12-31 | 13G | Roivant Sciences Ltd. ROIV | Dexcel Pharma Technologies Ltd. | 102,849,443 12.780% | 0 (Unchanged) | Filing |
| 2023-02-14 4:08 pm Purchase | 2022-12-31 | 13G | Roivant Sciences Ltd. ROIV | Dexcel Pharma Technologies Ltd. | 102,849,443 14.150% | 4,040,285 (+4.09%) | Filing |
| 2022-02-10 4:26 pm Purchase | 2021-12-31 | 13G | Roivant Sciences Ltd. ROIV | Dexcel Pharma Technologies Ltd. | 98,809,158 14.280% | 98,809,158 (New Position) | Filing |